{
  "abstract": "Immune checkpoint immunotherapy has transformed contemporary oncology, establishing a new paradigm across diverse malignancies. P-selectin glycoprotein ligand-1 (PSGL-1; CD162) emerged as a new immunotherapeutic target. Initially characterized as a glycosylated selectin ligand controlling leukocyte rolling, adhesion, and trafficking, PSGL-1 is now recognized as a multifunctional immunoregulatory receptor with therapeutic relevance in cancer. Its mucin-like structure, specific glycosylation, tyrosine sulfation, and cellular context enable functional interactions with several ligands, including selectins and V-domain immunoglobulin suppressor of T cell activation (VISTA). PSGL-1 is known to shape immune homeostasis, T-cell activation, effector and memory T-cell differentiation, myeloid-cell function, and tumor immune evasion. In chronic infection and cancer models, PSGL-1 restrains antigen-driven T-cell responses and contributes to dysfunctional or exhausted T-cell states, supporting its classification as a checkpoint-like regulator of immunity. Importantly, genetic deletion or antibody-mediated blockade of PSGL-1 enhances anti-tumor immunity in preclinical cancer models by increasing tumor-infiltrating T-cell activation and promoting immunostimulatory myeloid phenotypes. These changes in tumor-infiltrating immune cells are associated with reduction of tumor growth, synergism with PD-1/PD-L1 blockade, and improvement of chimeric antigen receptor (CAR) T-cell therapy. In blood cancers, where PSGL-1 is often expressed in malignant cells, PSGL-1 contributes to malignant cell homing, tissue dissemination, chemoresistance, and antibody-induced tumor-cell apoptosis. Overall, PSGL-1 represents a promising candidate for next-generation cancer immunotherapy, with potential to stimulate anti-tumor immunity, remodel the tumor microenvironment, and target malignant hematopoietic cell properties.",
  "abstract_shown": true,
  "affiliations": [
    "i3S-Instituto de Investigação e Inovação em Saúde, Universidade do Porto, Porto, Portugal."
  ],
  "article_type": "review article",
  "arxiv": null,
  "author_total": 2,
  "authors": [
    {
      "affs": [
        0
      ],
      "name": "João L Pereira",
      "orcid": "0000-0002-8625-5420"
    },
    {
      "affs": [
        0
      ],
      "name": "Nuno R Dos Santos",
      "orcid": "0000-0001-7347-2592"
    }
  ],
  "bibtex": "https://research.draconitic.com/paper/93ychx1bw6dq1.bib",
  "cited_by": 0,
  "doi": "10.1093/immadv/ltag023",
  "fulltext_url": "https://europepmc.org/articles/PMC13685773",
  "id": "93ychx1bw6dq1",
  "issns": [
    "2732-4303"
  ],
  "landing_url": "https://europepmc.org/article/MED/42909984",
  "language": "eng",
  "licence": "CC-BY-NC",
  "licence_label": "CC BY-NC",
  "licence_source": "article",
  "licence_url": "https://creativecommons.org/licenses/by-nc/4.0/",
  "metadata_licence": null,
  "native_subjects": [
    [
      "openalex",
      "2730|Cancer Immunotherapy and Biomarkers"
    ]
  ],
  "openalex": "W7221347602",
  "pdf_url": "https://europepmc.org/articles/PMC13685773?pdf=render",
  "pmcid": "PMC13685773",
  "pmid": "42909984",
  "published": "2026-10-10",
  "publisher": null,
  "ris": "https://research.draconitic.com/paper/93ychx1bw6dq1.ris",
  "sources": [
    {
      "first_seen": "2026-10-30T12:20:10Z",
      "native_id": "MED:42909984",
      "source": "europepmc",
      "url": "https://europepmc.org/article/MED/42909984"
    }
  ],
  "subjects": [
    {
      "field": "medicine",
      "origin": "openalex:2730|Cancer Immunotherapy and Biomarkers",
      "subfield": "oncology"
    }
  ],
  "title": "Targeting the PSGL-1 glycoprotein in cancer: cellular mechanisms and emerging immunotherapeutic strategies.",
  "title_text": "Targeting the PSGL-1 glycoprotein in cancer: cellular mechanisms and emerging immunotherapeutic strategies.",
  "type": "peer-reviewed",
  "updated_at": "2026-10-30T12:20:10Z",
  "url": "https://research.draconitic.com/paper/93ychx1bw6dq1",
  "venue": "Immunotherapy advances",
  "versions": []
}